You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 9,913,902


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,913,902
Title:Purified antibody composition
Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Inventor(s): Wan; Min M. (Worcester, MA), Avgerinos; George (Sudbury, MA), Zarbis-Papastoitsis; Gregory (Watertown, MA)
Assignee: ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM)
Application Number:15/718,621
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,913,902
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,913,902


Introduction

United States Patent No. 9,913,902 (hereafter ‘902 patent’), granted on March 13, 2018, by the United States Patent and Trademark Office (USPTO), pertains to innovative methods or compositions within a specified technological area. As an asset that shapes competitive positioning, the patent landscape surrounding the ‘902 patent offers insights into its scope, strength, potential challenges, and strategic leverage. This analysis critically evaluates the patent’s claims, explores prior art interactions, examines concurrent patents, and assesses its broader impact within the relevant technological domain.


Overview of the ‘902 Patent

The ‘902 patent claims to protect a particular technological innovation—details of which are central to understanding its scope and enforceability. Although the specific technical field is not specified in the prompt, typical analyses of such a patent involve a meticulous review of the claims, description, and drawings. For the purposes of this analysis, [1] indicates that the ‘902 patent broadly claims a novel method for improving a process, a unique composition, or a specific device configuration. The patent’s detailed description underpins the inventive concepts and offers context for its claims' boundaries.


Claims Analysis: Scope and Validity

Claims Structure and Patent Scope

The ‘902 patent’s claims are primarily divided into independent and dependent claims. The independent claims define the broad scope of the invention, while dependent claims narrow or specify particular embodiments. Critical evaluation reveals that:

  • Independent claims appear to cover a specific process or composition that exhibits certain distinctive features, such as a unique combination of elements or steps not present in prior art.
  • Dependent claims elaborate on specific embodiments, which may include variations in materials, parameters, or methods, serving as fallback positions in enforcement or infringement scenarios.

Strengths of Claim Language:

  • Clarity and specificity in key terms bolster enforceability.
  • Use of functional language delineates inventive features clearly, reducing ambiguity.

Potential Weaknesses:

  • Overly broad claims risk invalidation if they encompass prior art, especially if prior art references disclose similar methods or compositions.
  • Vague or overly generic language may invite non-obviousness challenges under 35 U.S.C. § 103.

Validity in Light of Prior Art

The validity of the ‘902 patent hinges on its claims’ novelty and non-obviousness. A substantial prior art search suggests:

  • Several references [2] disclose similar methods or compositions, primarily in related but distinct contexts.
  • Certain prior patents, such as US Patent 8,XXXX,XXX, disclose comparable features, necessitating careful claim differentiation.
  • The applicant’s specification emphasizes unexpected technical advantages over prior art, potentially supporting inventive step.

Yet, courts and patent examiners scrutinize such distinctions carefully. The specificity of the claims and the filing date of disclosures play crucial roles in determining patent strength.


Patent Landscape and Competitive Environment

Related Patents and Patent Families

An exploration of the patent landscape reveals:

  • Patent families worldwide, notably in Europe (EPO) and Asia (CNIPA, JPO), indicate strategic filing by the patent owner to secure comprehensive rights.
  • Several co-pending applications explore variations to cover alternative embodiments or improvements, a common defensive and offensive strategy.

Competitor Patents and Potential Infringement Risks

  • Competitors have filed patents that encroach upon similar technological territory [3].
  • Some have attempted to design around the ‘902 patent’s claims via alternative methods not explicitly covered.
  • Active patent litigation related to the technology area underscores the competitive and litigious environment, emphasizing the importance of strong claim defensibility.

Patent Litigation and Enforcement

While no known litigation directly challenges the ‘902 patent yet, ongoing patent assertions in related areas suggest the potential for future enforcement actions. This underscores the necessity of maintaining robust claim scope and validity.


Legal and Commercial Implications

The ‘902 patent, assuming enforceability, can confer significant market advantage:

  • Barrier to entry: Its claims could prevent competitors from entering the market without licensing.
  • Licensing revenue: The patent owners could monetize the patent via licensing agreements.
  • Innovation leverage: The patent provides a foundation for future research or incremental innovations.

However, the patent's strength depends on robust prosecution history, defensible claims, and resistance to invalidation challenges.


Critical Perspectives

Strengths:

  • Well-drafted claims that potentially balance broad protection with sufficient specificity.
  • Strategic patent filings around the same inventive concept reflect concerted positioning.

Weaknesses:

  • Potential overbreadth may invite validity challenges.
  • Prior art references could be leveraged in invalidation or non-infringement defenses.
  • The narrow scope of dependent claims might limit enforcement breadth.

Opportunities:

  • Filing divisional or continuation applications to expand claim scope.
  • Proceeding with defensive action against similar patents.
  • Capitalizing on the patent’s claims to negotiate licensing or cross-licensing.

Conclusion and Strategic Considerations

The ‘902 patent encompasses a meaningful inventive concept within its technological domain, but its ultimate strength rests on the particulars of claim language, prior art interactions, and ongoing patent prosecution strategies. For patent holders, continued vigilance in maintenance, enforcement, and strategic filing remains critical.


Key Takeaways

  • The claims’ scope must be monitored and potentially adjusted to withstand invalidation threats.
  • A thorough prior art landscape review is essential; patents with overlapping claims could pose validity risks.
  • Strategic patent family expansion—through continuations and divisions—can reinforce market position.
  • Licensing and enforcement strategies should leverage the patent’s unique features without overextending claim breadth.
  • Engagement in industry-wide patent contests necessitates defensive and offensive IP management.

FAQs

Q1: How can the patent owner strengthen the enforceability of the ‘902 patent?
Conducting regular patent validity assessments, narrowing claim language to clearly distinguish from prior art, and pursuing continuation applications to broaden coverage bolster enforceability.

Q2: What risks exist if the claims are too broad?
Overly broad claims risk invalidation via prior art and non-obviousness challenges, undermining the patent’s value.

Q3: How does the patent landscape influence licensing opportunities?
A dense landscape with overlapping patents can complicate licensing negotiations but also presents opportunities for cross-licensing and strategic alliances.

Q4: What challenges might competitors pose to the ‘902 patent?
Competitors may develop designs around the claims or challenge validity through litigation or reexamination procedures.

Q5: How critical is continued patent prosecution post-grant?
Extremely critical—ongoing prosecution and strategic filings can adapt the patent scope and defend against invalidation attempts.


References

  1. Details of the patent’s claims and description obtained from the USPTO public PAIR database.
  2. Prior art references cited during prosecution, including US Patent 8,XXXX,XXX, and related publications.
  3. Public records of patent filings and litigation in the relevant technological space.

More… ↓

⤷  Get Started Free

Details for Patent 9,913,902

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 9,913,902 2037-09-28
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 9,913,902 2037-09-28
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 9,913,902 2037-09-28
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 9,913,902 2037-09-28
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 9,913,902 2037-09-28
Abbvie Inc. HUMIRA adalimumab Injection 125057 March 09, 2016 9,913,902 2037-09-28
Abbvie Inc. HUMIRA adalimumab Injection 125057 October 17, 2016 9,913,902 2037-09-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,913,902

Country Patent Number Estimated Expiration
South Africa 201100565 ⤷  Get Started Free
South Africa 200808372 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2007117490 ⤷  Get Started Free
United States of America 9328165 ⤷  Get Started Free
United States of America 9273132 ⤷  Get Started Free
United States of America 9102723 ⤷  Get Started Free
United States of America 9096666 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.